Nurix Therapeutics (NRIX) Change in Accured Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Change in Accured Expenses data on file, last reported at $4.1 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $4.1 million, down 40.63% year-over-year; the trailing twelve-month figure through Feb 2026 was $14.5 million (down 4.42% YoY), and the FY2025 annual result was $17.3 million, up 46.5% from the prior year.
• Change in Accured Expenses retreated to $4.1 million in Q1 2026 per NRIX's latest filing, from $11.0 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $11.0 million in Q4 2025 and troughed at -$7.0 million in Q2 2025.
• A 5-year average of $2.6 million and a median of $3.6 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 314.68% in 2022, then tumbled 402.88% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $3.3 million in 2022, then dropped by 6.71% to $3.1 million in 2023, then surged by 193.46% to $9.0 million in 2024, then gained by 22.36% to $11.0 million in 2025, then plunged by 62.7% to $4.1 million in 2026.
• Business Quant data shows NRIX's Change in Accured Expenses at $4.1 million in Q1 2026, $11.0 million in Q4 2025, and $6.3 million in Q3 2025.